(Q37762245)

22 August 2017

1 reference

title

Pharmacotherapy for hepatic encephalopathy (English)

1 reference

22 August 2017

0 references

Paula V Phongsamran

1

1 reference

22 August 2017

Jiwon W Kim

series ordinal

2

1 reference

22 August 2017

Jennifer Cupo Abbott

series ordinal

3

1 reference

22 August 2017

Angela Rosenblatt

series ordinal

4

1 reference

22 August 2017

publication date

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

70

1 reference

22 August 2017

issue

9

1 reference

22 August 2017

page(s)

1131-1148

1 reference

https://scigraph.springernature.com/pub.10.2165/10898630-000000000-00000

22 August 2017

exact match

0 references

cites work

Review article: the current pharmacological therapies for hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.2165%2F10898630-000000000-00000

Deafness Complicating Antibiotic Therapy of Hepatic Encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F10898630-000000000-00000

Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F10898630-000000000-00000

The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F10898630-000000000-00000

Effects of L-carnitine in patients with hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F10898630-000000000-00000

A randomized controlled trial of acarbose in hepatic encephalopathy

21 January 2018

1 reference

12 December 2020

Benzodiazepine receptor antagonists for hepatic encephalopathy

1 reference

12 December 2020

Rifaximin--a novel antimicrobial for enteric infections

1 reference

12 December 2020

Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study

1 reference

12 December 2020

Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy

1 reference

12 December 2020

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial

1 reference

12 December 2020

Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial

1 reference

12 December 2020

Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy

1 reference

12 December 2020

Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo

1 reference

12 December 2020

Serum zinc levels in hepatic encephalopathy

1 reference

12 December 2020

Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt

1 reference

12 December 2020

Rifaximin: in vitro and in vivo antibacterial activity--a review

1 reference

12 December 2020

Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy

1 reference

12 December 2020

Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study

1 reference

12 December 2020

Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial

1 reference

12 December 2020

Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis

1 reference

12 December 2020

Lactulose, disaccharides and colonic flora. Clinical consequences

1 reference

12 December 2020

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic

1 reference

12 December 2020

Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy

1 reference

12 December 2020

Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial

1 reference

12 December 2020

Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study

1 reference

12 December 2020

Treatment of hepatic encephalopathy with metronidazole

1 reference

12 December 2020

Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis

1 reference

12 December 2020

Ammonia: key factor in the pathogenesis of hepatic encephalopathy

1 reference

12 December 2020

Probiotic yogurt for the treatment of minimal hepatic encephalopathy.

1 reference

12 December 2020

Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial

1 reference

12 December 2020

Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial

1 reference

12 December 2020

Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy

1 reference

12 December 2020

Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study

1 reference

12 December 2020

Overt hepatic encephalopathy precipitated by zinc deficiency

1 reference

12 December 2020

Neomycin in the treatment of hepatic coma

1 reference

12 December 2020

Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.

1 reference

12 December 2020

Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

1 reference

12 December 2020

Hepatic encephalopathy. Metabolic consequence of cirrhosis often is reversible

1 reference

12 December 2020

Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders

1 reference

12 December 2020

Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group

1 reference

12 December 2020

Effect of L-carnitine upon ammonia tolerance test in cirrhotic patients

1 reference

12 December 2020

Home lactulose enema: prevention of hepatic encephalopathy at home

1 reference

12 December 2020

Memantine, a noncompetitive NMDA receptor antagonist improves hyperammonemia-induced encephalopathy and acute hepatic encephalopathy in rats.

1 reference

12 December 2020

Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study

1 reference

12 December 2020

Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose

1 reference

12 December 2020

Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study

1 reference

12 December 2020

Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study

1 reference

12 December 2020

Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

1 reference

12 December 2020

Hyperammonaemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: a unified theory of portal-systemic encephalopathy

1 reference

12 December 2020

Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design

1 reference

12 December 2020

Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study

1 reference

12 December 2020

Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy

1 reference

12 December 2020

Treatment of hepatic encephalopathy

1 reference

12 December 2020

Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy

1 reference

12 December 2020

Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy.

1 reference

12 December 2020

Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.

1 reference

12 December 2020

Hepatic Encephalopathy.

1 reference

12 December 2020

An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy

1 reference

12 December 2020

Rifaximin treatment in hepatic encephalopathy

1 reference

12 December 2020

Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial

1 reference

12 December 2020

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

1 reference

12 December 2020

Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.

1 reference

12 December 2020

Role of manganese in the pathogenesis of portal-systemic encephalopathy

1 reference

12 December 2020

Branched-chain amino acids for hepatic encephalopathy

1 reference

12 December 2020

Diagnosis and therapy of hepatic encephalopathy.

1 reference

12 December 2020

Branched chain amino acids in the management of chronic liver disease. Facts and fantasies

1 reference

12 December 2020

Treatment of hepatic encephalopathy

1 reference

12 December 2020

Hepatic encephalopathy

1 reference

12 December 2020

Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?

1 reference

12 December 2020

Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis

1 reference

12 December 2020

The treatment of hepatic encephalopathy

1 reference

12 December 2020

Audiotoxicity and Nephrotoxicity Due to Orally Administered Neomycin

1 reference

12 December 2020

Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial

1 reference

12 December 2020

Flumazenil therapy for hepatic encephalopathy. A double-blind cross over study

1 reference

12 December 2020

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential

1 reference

12 December 2020

Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study

1 reference

12 December 2020

Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial.

1 reference

12 December 2020

Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy

1 reference

12 December 2020

Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial

1 reference

12 December 2020

Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial

1 reference

12 December 2020

10.2165/10898630-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

22 August 2017

1006404398

0 references

1 reference